Company intelligence / Profile preview
Infex Therapeutics
Alderley Edge, Cheshire, United Kingdominfextx.com ↗
- Ownership
- Private
- Employees
- ~11-50
- Development stage
- Phase 2
01
Overview
Infex Therapeutics is advancing multiple programs including RESP-X (COT-143) in Phase 2a for non-cystic fibrosis bronchiectasis (NCFB) patients with Pseudomonas aeruginosa colonization, and MET-X in preclinical development for gram-negative bacterial infections with FDA QIDP designation.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule drugMonoclonal antibodyAntitoxinMicrobiotaVirus-like Drug Conjugates (VDCs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Venus Remedies LtdJustus-Liebig-University GiessenShionogiMedivir AB
Beyond the preview
Go deeper on Infex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infex Therapeutics.